Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography.
An analytical method has been developed and validated for the quantitation of CP-88,059 in human serum. The compound and internal standard were extracted from serum by solid-phase extraction with a weak cation-exchange phase. The analytes were resolved from endogenous interferences using narrow-bore (2.1 mm I.D.) C18 reversed-phase HPLC. Column effluent was monitored by UV absorbance detection at 215 nm. The standard curve range was 1 to 250 ng/ml. The accuracy and precision values for the method were within +/- 10% and +/- 15%, respectively. A four-fold detectability enhancement was achieved using a 2.1 mm I.D. HPLC column relative to the more common 4.6 mm I.D. column. A performance comparison was made between the 2.1 mm I.D. column used for validation and a 4.6 mm I.D. column with the same stationary phase.
Janiszewski
J S
JS
Pfizer Central Research, Department of Drug Metabolism and Clinical Measurements, Groton, CT 06340, USA.
Fouda
H G
HG
Cole
R O
RO
D014150:Antipsychotic Agents / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D010879:Piperazines / Q000097:blood*; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet; D013141:Spiro Compounds / Q000097:blood*; D013844:Thiazoles
D014150:Antipsychotic Agents; D010879:Piperazines; D013141:Spiro Compounds; D013844:Thiazoles; C092292:ziprasidone